oncology
Medicines

Survival benefit for daytime vs evening infusions of checkpoint inhibitors

The timing of immune checkpoint inhibitor infusions may be crucial to outcomes, according to findings from a study that found a significant survival benefit associated with daytime compared to evening administration of therapy for patients with advanced melanoma. In a retrospective study, oncologists at the Winship Cancer Institute of Emory University, Atlanta, Georgia, analysed outcomes ...

Already a member?

Login to keep reading.


OR
© 2022 the limbic